Merck gets on the Treg train with Pandion buy
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
World Symposium – Orchard leads the crop of Hurler syndrome hopefuls
Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.
Merck’s Covid-19 vaccines head for the scrapheap
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Mersana starts to lose its shine
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
